Roche commences tender offer for all shares of 89bio, Inc. for $14.50 per share in cash, plus a non-tradeable contingent value right for up to $6.00 per share in cash
Basel, 1 October 2025 - Roche ( SIX: RO, ROG. OTCQX: RHHBY ) announced today that it has commenced a tender offer for all of the outstanding shares of common stock of 89bio, Inc. ( 89bio ) ( NASDAQ: ETNB ) at a price of $14.50 per share in cash, plus a non-tradeable contingent value right ( CVR ) ...
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger - PGRE, BRY, ETNB, and COMP
NEW YORK, Sept. 26, 2025 ( GLOBE NEWSWIRE ) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC ( the "M&A Class Action Firm" ) , has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report.
Zacks Industry Outlook Highlights Halozyme Therapeutics, Akero Therapeutics, Kiniska Pharmaceuticals, ANI Pharmaceuticals and Twist BioScience
Biotech stocks gain momentum as M&A, AI-driven drug discovery, and new approvals fuel growth. Halozyme, Akero, Kiniska, ANI and Twist stand out.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PGRE, BERY, COMP, ETNB on Behalf of Shareholders - Compass ( NYSE:COMP )
NEW YORK, Sept. 23, 2025 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Paramount Group, Inc.
5 Biotech Stocks Worth Adding to Your Portfolio Now
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position HALO, AKRO, KSNA, ANIP and TWST in this volatile sector ...
Deal Dispatch: Want M&A Approval? FCC Chair Explains How - Anebulo Pharmaceuticals ( NASDAQ:ANEB ) , Walt Disney ( NYSE:DIS )
A late-night comedy show's cancellation has reignited deal drama, with reports of tit-for-tat maneuvering between major corporations and regulators holding the power to say yea or nay to M&A activity.
This United Parcel Service Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Friday - 89bio ( NASDAQ:ETNB ) , Replimune Group ( NASDAQ:REPL )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. BMO Capital analyst Fadi Chamoun downgraded United Parcel Service, Inc.
Roche To Acquire 89bio For $2.4 Billion In Liver And Cardiometabolic Push - 89bio ( NASDAQ:ETNB ) , Roche Holding ( OTC:RHHBY )
Roche is acquiring 89bio for $14.50/share, a 79% premium. The deal could reach $3.5 billion with milestone payments tied to pegozafermin sales. Up Next: Wall Street trader's 35-0 strategy goes public this week. See it first → On Thursday, Roche Holdings AG RHHBY agreed to acquire 89bio, Inc.
Gold Falls Over 1%; Darden Posts Downbeat Earnings - BioCardia ( NASDAQ:BCDA ) , Aptevo Therapeutics ( NASDAQ:APVO )
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 150 points on Thursday. The Dow traded up 0.37% to 46,190.85 while the NASDAQ rose 1.07% to 22,500.28. The S&P 500 also rose, gaining, 0.62% to 6,641.29. Information technology shares jumped by 0.8% on ...
RHHBY to Acquire 89bio for $3.5B, Add Late-Stage MASH Drug to Pipeline
Roche is set to acquire 89bio for $3.5B, adding late-stage MASH drug pegozafermin to its cardiovascular, renal, and metabolic pipeline.
Radian Group, Intel, Nanobiotix, CrowdStrike And Other Big Stocks Moving Higher On Thursday - Altimmune ( NASDAQ:ALT ) , ASML Holding ( NASDAQ:ASML )
U.S. stocks were higher, with the Nasdaq Composite gaining more than 200 points on Thursday. Shares of Radian Group Inc. RDN rose sharply during Thursday's session after the company announced it entered into a definitive agreement to acquire Inigo for $1.7 billion.
Nasdaq Surges 100 Points; Bionano Genomics Shares Plunge - Aptevo Therapeutics ( NASDAQ:APVO ) , Aeries Technology ( NASDAQ:AERT )
U.S. stocks traded mostly higher this morning, with the Nasdaq Composite gaining more than 100 points on Thursday. Following the market opening Thursday, the Dow traded down 0.04% to 46,000.59 while the NASDAQ rose 0.49% to 22,370.12. The S&P 500 also rose, gaining, 0.29% to 6,619.34.
Stock Market Today: S&P 500, Nasdaq, Dow Futures Jump Following Fed Rate Cut-Broadcom, Cracker Barrel, FedEx In Focus - SPDR S&P 500 ( ARCA:SPY )
U.S. stock futures advanced on Thursday following Wednesday's mixed moves. Futures of major benchmark indices were higher.
Why Bullish Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket - Angel Studios ( NYSE:ANGX ) , Aptevo Therapeutics ( NASDAQ:APVO )
Shares of Bullish BLSH rose sharply in pre-market trading after the company posted a profit for the second quarter after Wednesday's closing bell. Bullish reported quarterly earnings of 93 cents per share, versus a year-ago loss of $1.03 per share.
Darden Restaurants, Factset Research And 3 Stocks To Watch Heading Into Thursday - Bullish ( NYSE:BLSH ) , Darden Restaurants ( NYSE:DRI )
With U.S. stock futures trading higher this morning on Thursday, some of the stocks that may grab investor focus today are as follows: Wall Street expects Darden Restaurants Inc. DRI to report quarterly earnings at $2.00 per share on revenue of $3.04 billion before the opening bell, according to ...
89bio, Inc. Announces Agreement to be Acquired by Roche - 89bio ( NASDAQ:ETNB )
- 89bio stockholders to receive up to $20.50 per share in cash, comprised of $14.50 per share in cash at closing and a non-tradeable contingent value right ( CVR ) to receive up to an aggregate of $6.00 per share in cash. transaction represents total equity value of up to approximately $3.5 ...
89bio, Inc. Announces Agreement to be Acquired by Roche
- 89bio stockholders to receive up to $20.50 per share in cash, comprised of $14.50 per share in cash at closing and a non-tradeable contingent value right ( CVR ) to receive up to an aggregate of $6.00 per share in cash. transaction represents total equity value of up to approximately $3.5 ...
Roche enters into a definitive merger agreement to acquire 89bio, and its phase 3 FGF21 analog for the therapy of moderate to severe MASH
Basel, 18 September 2025 - Roche ( SIX: RO, ROG. OTCQX: RHHBY ) announced today that it has entered into a definitive merger agreement to acquire 89bio, Inc. ( Nasdaq: ETNB ) , a publicly listed clinical-stage biopharmaceutical company pioneering the development of innovative therapies for the ...
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN FRANCISCO, Sept. 05, 2025 ( GLOBE NEWSWIRE ) -- 89bio, Inc. ( the "Company" or "89bio" ) ( Nasdaq: ETNB ) , a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today ...
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN FRANCISCO, July 09, 2025 ( GLOBE NEWSWIRE ) -- 89bio, Inc. ( the "Company" or "89bio" ) ( Nasdaq: ETNB ) , a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today ...
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN FRANCISCO, June 06, 2025 ( GLOBE NEWSWIRE ) -- 89bio, Inc. ( the "Company" or "89bio" ) ( Nasdaq: ETNB ) , a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today ...
Why Vertiv Holdings Shares Are Trading Higher By 17%; Here Are 20 Stocks Moving Premarket - AgriFORCE Growing Systems ( NASDAQ:AGRI ) , AGM Gr Hldgs ( NASDAQ:AGMH )
Shares of Vertiv Holdings Co VRT rose sharply in today's pre-market trading after the company reported better-than-expected first-quarter financial results and raised its full-year sales guidance. Vertiv reported quarterly earnings of 64 cents per share which beat the analyst consensus estimate ...
89bio, Inc. Announces Pricing of $250.0 Million Public Offering of Common Stock and Pre-Funded Warrants - 89bio ( NASDAQ:ETNB )
SAN FRANCISCO, Jan. 28, 2025 ( GLOBE NEWSWIRE ) -- 89bio, Inc. ( "89bio" ) ETNB, a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the pricing of its ...
89bio, Inc. Announces Pricing of $250.0 Million Public Offering of Common Stock and Pre-Funded Warrants
SAN FRANCISCO, Jan. 28, 2025 ( GLOBE NEWSWIRE ) -- 89bio, Inc. ( "89bio" ) ( Nasdaq: ETNB ) , a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the pricing ...
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants - 89bio ( NASDAQ:ETNB )
SAN FRANCISCO, Jan. 27, 2025 ( GLOBE NEWSWIRE ) -- 89bio, Inc. ( "89bio" ) ETNB, a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that it has commenced an ...
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
SAN FRANCISCO, Jan. 27, 2025 ( GLOBE NEWSWIRE ) -- 89bio, Inc. ( "89bio" ) ( Nasdaq: ETNB ) , a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that it has ...
Dada Nexus, Titan Machinery, AT&T And Other Big Stocks Moving Higher On Monday - Dada Nexus ( NASDAQ:DADA ) , Akero Therapeutics ( NASDAQ:AKRO )
U.S. stocks were lower, with the Dow Jones index falling over 100 points on Monday. Shares of Dada Nexus Limited DADA rose sharply during Monday's session after the company received a preliminary, non-binding proposal from JD.com, Inc.
Nasdaq Dips 3%; Chicago Fed National Activity Index Rises In December - Allakos ( NASDAQ:ALLK ) , Akero Therapeutics ( NASDAQ:AKRO )
U.S. stocks traded lower this morning, with the Nasdaq Composite falling over 600 points on Monday. Following the market opening Monday, the Dow traded down 0.33% to 44,276.05 while the NASDAQ fell 3.08% to 19,340.76. The S&P 500 also fell, dropping, 1.74% to 5,994.91.
New Strong Sell Stocks for January 7th
ETNB, ATUS and ASH have been added to the Zacks Rank #5 (Strong Sell) List on January 7, 2024.
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN FRANCISCO, Dec. 19, 2024 ( GLOBE NEWSWIRE ) -- 89bio, Inc. ( the "Company" or "89bio" ) ( Nasdaq: ETNB ) , a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today ...
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN FRANCISCO, Nov. 29, 2024 ( GLOBE NEWSWIRE ) -- 89bio, Inc. ( the "Company" or "89bio" ) ( Nasdaq: ETNB ) , a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today ...
89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024 - 89bio ( NASDAQ:ETNB )
SAN FRANCISCO, Nov. 15, 2024 ( GLOBE NEWSWIRE ) -- 89bio, Inc.
89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024
New post-hoc analyses reinforce pegozafermin's potential anti-fibrotic effects and the potential utility of non-invasive tests which correlate to histological endpoints New post-hoc analyses reinforce pegozafermin's potential anti-fibrotic effects and the potential utility of non-invasive tests ...
89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants
SAN FRANCISCO, Nov. 12, 2024 ( GLOBE NEWSWIRE ) -- 89bio, Inc. ( "89bio" ) ( Nasdaq: ETNB ) , a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the pricing ...
89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants
SAN FRANCISCO, Nov. 12, 2024 ( GLOBE NEWSWIRE ) -- 89bio, Inc. ( "89bio" ) ( Nasdaq: ETNB ) , a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the pricing ...
89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis ( MASH ) at AASLD The Liver Meeting® 2024
SAN FRANCISCO, Oct. 15, 2024 ( GLOBE NEWSWIRE ) -- 89bio, Inc. ( Nasdaq: ETNB ) , a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that new analyses of data ...
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - 89bio ( NASDAQ:ETNB )
SAN FRANCISCO, Oct. 11, 2024 ( GLOBE NEWSWIRE ) -- 89bio, Inc. ( the "Company" or "89bio" ) ETNB, a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the ...
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN FRANCISCO, Oct. 11, 2024 ( GLOBE NEWSWIRE ) -- 89bio, Inc. ( the "Company" or "89bio" ) ( Nasdaq: ETNB ) , a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today ...
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN FRANCISCO, Sept. 19, 2024 ( GLOBE NEWSWIRE ) -- 89bio, Inc. ( the "Company" or "89bio" ) ( Nasdaq: ETNB ) , a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today ...
89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer
SAN FRANCISCO, Sept. 16, 2024 ( GLOBE NEWSWIRE ) -- 89bio, Inc. ( Nasdaq: ETNB ) , a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, announced the appointment of Teresa ...
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN FRANCISCO, Aug. 09, 2024 ( GLOBE NEWSWIRE ) -- 89bio, Inc. ( the "Company" or "89bio" ) ( Nasdaq: ETNB ) , a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today ...
89bio Appoints Francis Sarena as Chief Operating Officer
SAN FRANCISCO, Aug. 07, 2024 ( GLOBE NEWSWIRE ) -- 89bio, Inc. ( Nasdaq: ETNB ) , a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the appointment of ...
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN FRANCISCO, July 12, 2024 ( GLOBE NEWSWIRE ) -- 89bio, Inc. ( the "Company" or "89bio" ) ( Nasdaq: ETNB ) , a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today ...
Is Madrigal Pharmaceuticals Stock a Buy?
The company could become a prominent player in the biotech industry, but that might take a while.
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN FRANCISCO, June 14, 2024 ( GLOBE NEWSWIRE ) -- 89bio, Inc. ( the "Company" or "89bio" ) ( Nasdaq: ETNB ) , a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today ...
What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday? - Eli Lilly and Co ( NYSE:LLY ) , Madrigal Pharmaceuticals ( NASDAQ:MDGL ) , Sagimet Biosciences ( NASDAQ:SGMT )
On Wednesday, the stocks of Madrigal Pharmaceuticals Inc MDGL and Sagimet Biosciences Inc SGMT are trading lower. At the EASL International Liver Congress 2024, Eli Lilly And Co LLY shared an abstract highlighting fibrosis results from a Phase 2 trial of tirzepatide in patients with metabolic ...
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN FRANCISCO, May 10, 2024 ( GLOBE NEWSWIRE ) -- 89bio, Inc. ( the "Company" or "89bio" ) ( Nasdaq: ETNB ) , a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today ...
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN FRANCISCO, April 05, 2024 ( GLOBE NEWSWIRE ) -- 89bio, Inc. ( the "Company" or "89bio" ) ( Nasdaq: ETNB ) , a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today ...
89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis ( MASH ) with Fibrosis and Compensated Cirrhosis
-PRIME status is supported by positive data from the Phase 2b ENLIVEN trial of ...
Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?
Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while.
